YK012 / Excyte - LARVOL DELTA

A Phase I Study of YK012 in Primary Membranous Nephropathy (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Excyte Biopharma Ltd

New P1 trial • Glomerulonephritis • Renal Disease

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus (clinicaltrials.gov) - P1/2 | N=189 | Not yet recruiting | Sponsor: Excyte Biopharma Ltd | N=144 ➔ 189

Enrollment change • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus (clinicaltrials.gov) - P1/2 | N=144 | Not yet recruiting | Sponsor: Excyte Biopharma Ltd

New P1/2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Study of YK012 in Primary Membranous Nephropathy (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Excyte Biopharma Ltd

New P1 trial • Glomerulonephritis • Renal Disease

Study of YK012 in B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=46 | Recruiting | Sponsor: Excyte Biopharma Ltd

New P1/2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Excyte Biopharma Ltd

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology